PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 250 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $380 | -8.4% | 12,087 | +4.1% | 0.01% | 0.0% |
| Q2 2023 | $415 | -12.8% | 11,611 | -0.4% | 0.01% | -18.2% |
| Q1 2023 | $476 | +20.2% | 11,660 | +13.7% | 0.01% | +10.0% |
| Q4 2022 | $396 | -99.9% | 10,256 | +6.1% | 0.01% | -28.6% |
| Q3 2022 | $514,000 | -10.6% | 9,662 | -1.9% | 0.01% | -6.7% |
| Q2 2022 | $575,000 | -23.9% | 9,853 | -0.5% | 0.02% | -11.8% |
| Q1 2022 | $756,000 | +171.9% | 9,903 | +114.4% | 0.02% | +183.3% |
| Q4 2021 | $278,000 | -51.4% | 4,620 | -54.8% | 0.01% | -53.8% |
| Q3 2021 | $572,000 | -8.5% | 10,210 | -0.9% | 0.01% | -13.3% |
| Q2 2021 | $625,000 | -14.9% | 10,300 | -1.6% | 0.02% | -16.7% |
| Q1 2021 | $734,000 | +19.3% | 10,470 | +1.8% | 0.02% | +12.5% |
| Q4 2020 | $615,000 | +133.8% | 10,280 | +135.2% | 0.02% | +128.6% |
| Q3 2020 | $263,000 | +19.5% | 4,370 | +4.0% | 0.01% | +16.7% |
| Q2 2020 | $220,000 | – | 4,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tamarack Advisers, LP | 360,000 | $21,845,000 | 6.19% |
| Gagnon Advisors, LLC | 213,217 | $12,938,000 | 4.92% |
| GAGNON SECURITIES LLC | 499,333 | $30,300,000 | 4.30% |
| Spyglass Capital Management LLC | 2,117,673 | $128,500,000 | 2.86% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 646,530 | $39,231,000 | 2.30% |
| Paulson & Co. | 1,273,161 | $77,255,000 | 1.85% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 212,112 | $12,871,000 | 1.44% |
| Tygh Capital Management, Inc. | 152,332 | $9,244,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,147,000 | $69,600,000 | 1.24% |
| Rock Springs Capital Management LP | 1,025,000 | $62,197,000 | 1.23% |